Related Experiment Videos
General and local scleroderma in children and dermatomyositis and associated syndromes
1University of Toronto, Division of Rheumatology, Hospital for Sick Children, Ontario, Canada.
Insights
Childhood scleroderma typically presents as localized disease, unlike adult systemic scleroderma. Current treatment strategies for localized scleroderma in children remain challenging, necessitating further research for improved therapies.
Area of Science:
- Pediatric rheumatology
- Dermatology
- Autoimmune diseases
Background:
- Childhood scleroderma predominantly manifests as localized disease, contrasting with the systemic form common in adults.
- Existing literature on pediatric scleroderma largely focuses on localized presentations.
- Optimal treatment strategies for localized scleroderma in children, including patient selection, therapeutic modalities, and response monitoring, are not well-defined.
Purpose of the Study:
- To review the current therapeutic approach for localized scleroderma in children.
- To discuss recent literature concerning juvenile dermatomyositis.
- To highlight the need for improved and less toxic treatments based on future pathobiological understanding.
Main Methods:
- Review of current therapeutic strategies for childhood localized scleroderma.
- Literature review of recent studies on juvenile dermatomyositis.
- Discussion of pathobiological insights relevant to treatment development.
Main Results:
- The management of localized scleroderma in children presents ongoing therapeutic dilemmas.
- Recent literature primarily addresses localized forms of childhood scleroderma.
- Advances in understanding disease pathobiology are anticipated to guide future treatment innovations.
Conclusions:
- The treatment of localized scleroderma in children requires careful consideration and remains an area of active clinical challenge.
- Further research into the pathobiology of juvenile scleroderma and dermatomyositis is crucial for developing more effective and safer treatments.
Abstract:
Scleroderma in children virtually always manifests in the form of localized disease, whereas adult scleroderma usually manifests as systemic disease. The recent literature on childhood scleroderma is limited almost exclusively to localized disease. The treatment of this disease remains a dilemma, especially with regard to which patients should be treated, how they should be treated, and how the treatment response should be monitored. Our current therapeutic approach is reviewed. The recent literature regarding juvenile dermatomyositis is discussed. New understanding of the pathobiology of this disease should lead to improved, less toxic treatments in the future.